phenyl-p-tolyldisulfone | 78190-78-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: phenyl-p-tolyldisulfone
• 英文别名: p-Tolyl-phenyl-disulfon；Phenyl-p-tolyl-disulfon；4-Methyl-diphenyldisulfon；1-(Benzenesulfonylsulfonyl)-4-methylbenzene
• CAS: 78190-78-0
• 化学式: C₁₃H₁₂O₄S₂
• 分子量: 296.368
• InChiKey: ANMBHXMCLKMUST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  85
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-Phenylsulfonyl-N'-p-tolylsulfonyl-hydrazin 在 硝酸 作用下， 反应 4.0h， 以67%的产率得到phenyl-p-tolyldisulfone
  参考文献：
  名称：

  Eine einfache und allgemeine Methode zur Herstellung von α-Disulfonen (R¹SO₂SO₂R²)

  摘要：

  一种简便通用的α-二砜制备方法 α-二砜（R1SO2SO2R2）的二烷基、二芳基及烷基芳基二砜可以通过硝酸氧化N,N′-二磺酰肼来轻松制备。该方法适用于硫原子上多种取代基（R1，R2）。

  DOI：

  10.1055/s-1993-25891

文献信息

• [EN] N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG<br/>[FR] MODULATEURS N-BENZYLBENZIMIDAZOLES DE PPARG
  申请人：RIPKA AMY S

  公开号：WO2013078233A1

  公开（公告）日：2013-05-30

  The invention provides molecular entities that bind with high affinity to PPARG (PPARϒ), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

  本发明提供了与PPARG（PPARϒ）高亲和力结合的分子实体，抑制cdk5介导的PPARG磷酸化，但不对PPARG产生激动作用。本发明的化合物可用于治疗PPARG在糖尿病或肥胖等病患中起作用的情况。本发明还提供了制备该化合物的方法、用于评估该化合物作为非激动性PPARG结合化合物的生物测定方法，以及制药组合物。
• [EN] PYRIDO [3,4-D] PYRIMIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE-13 INHIBITORS<br/>[FR] DERIVES DE PYRIDO[3,4-D]PYRIMIDINE UTILES COMME INHIBITEURS DE LA METALLOPROTEINASE-13 DE MATRICE
  申请人：WARNER LAMBERT CO

  公开号：WO2005016926A1

  公开（公告）日：2005-02-24

  This invention relates to a pyrido[3,4-d]pyrimidine derivative of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R, L', L2, V, L3, and R2 are as defined in the specification, that inhibits a matrix metalloproteinase-13 enzyme and thus is useful for treating diseases resulting from MMP-13 mediated tissue breakdown such as osteoarthritis, rheumatoid arthritis, cartilage damage, psoriatic arthritis, ankylosing spondylitis, heart failure, atherosclerosis, inflammatory bowel disease, multiple sclerosis, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, cancer, and osteoporosis.

  该发明涉及一种Formula (I)的吡啶并[3,4-d]嘧啶衍生物，或其药用可接受盐，其中R、L'、L2、V、L3和R2如规范中所定义，该衍生物抑制基质金属蛋白酶-13酶，因此可用于治疗由MMP-13介导的组织分解引起的疾病，如骨关节炎、类风湿性关节炎、软骨损伤、银屑病性关节炎、强直性脊柱炎、心力衰竭、动脉粥样硬化、炎性肠病、多发性硬化、年龄相关性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周疾病、银屑病、癌症和骨质疏松症。
• Direct conversion of sulfinic acid to sulfonic acid derivatives.
  作者：MITURU FURUKAWA、MASUMI NISHIKAWA、YASUNOBU INABA、YOSHIHIDE NOGUCHI、TADASHI OKAWARA、TAIZO HITOSHI

  DOI：10.1248/cpb.29.623

  日期：——

  The reaction of sulfinic acid (1) with methanol in the presence of NCS-DMS gave methyl sulfinate (2) and methyl sulfonate (3) in 22% and 45% yields, respectively. Similarly, 1 reacted with morpholine under the same conditions to give the corresponding sulfinamide (5) and sulfonamide (6) in 23% and 50% yields. In these reactions, the disulfone (4) was also obtained as a minor product in some cases. The formation of sulfonic acid derivatives and disulfone was found to proceed through the intermediate formation of the sulfonyl chloride (7). The formation mechanism of sulfinic acid derivatives is also discussed.

  在 NCS-DMS 存在下，亚硫酸（1）与甲醇反应生成亚磺酸甲酯（2）和磺酸甲酯（3），产率分别为 22% 和 45%。同样，在相同条件下，1 与吗啉反应，得到相应的亚磺酰胺 (5) 和磺酰胺 (6)，收率分别为 23% 和 50%。在这些反应中，二砜（4）在某些情况下也会作为次要产物出现。研究发现，磺酸衍生物和二砜的形成是通过中间体磺酰氯（7）的形成进行的。此外，还讨论了亚磺酸衍生物的形成机理。
• [EN] NEW INTERMEDIATE COMPOUND FOR PREPARING VITAMIN B6<br/>[FR] NOUVEAU COMPOSÉ INTERMÉDIAIRE POUR LA PRÉPARATION DE VITAMINE B6
  申请人：DSM IP ASSETS BV

  公开号：WO2013163889A1

  公开（公告）日：2013-11-07

  Provided is a new intermediate compound for preparing vitamin B6, which can be used to synthesize the known intermediate compound for preparing vitamin B6, 4-methyloxazole-5-carboxyLate. Further provided is a process for preparing the new intermediate compound and a process for preparing the known intermediate compound 4-methyloxazole-5-carboxylate from the new intermediate compound.

  提供了一种新的中间化合物，用于制备维生素B6，可用于合成用于制备维生素B6的已知中间化合物4-甲氧咪唑-5-羧酸。进一步提供了制备新中间化合物的方法以及从新中间化合物制备已知中间化合物4-甲氧咪唑-5-羧酸的方法。
• Pyrido[3,4-d]pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
  申请人：Bunker Mae Amy

  公开号：US20050085447A1

  公开（公告）日：2005-04-21

  This invention relates to a pyrido[3,4-d]pyrimidine derivative of Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , L 1 , L 2 , V, L 3 , and R 2 are as defined in the specification, that inhibits a matrix metalloproteinase-13 enzyme and thus is useful for treating diseases resulting from MMP-13 mediated tissue breakdown such as osteoarthritis, rheumatoid arthritis, cartilage damage, psoriatic arthritis, ankylosing spondylitis, heart failure, atherosclerosis, inflammatory bowel disease, multiple sclerosis, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, cancer, and osteoporosis.

  本发明涉及一种式I的吡啶并[3,4-d]嘧啶衍生物或其药学上可接受的盐，其中R1、L1、L2、V、L3和R2如规范中所定义，该衍生物抑制基质金属蛋白酶-13酶，因此可用于治疗由MMP-13介导的组织分解引起的疾病，如骨关节炎、类风湿性关节炎、软骨损伤、银屑病性关节炎、强直性脊柱炎、心力衰竭、动脉粥样硬化、炎性肠病、多发性硬化症、年龄相关性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周疾病、银屑病、癌症和骨质疏松症。